newsfilter
← Latest News
Business Wire·

Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026

  • Aurinia Pharmaceuticals Inc. will report financial results for the three and twelve months ended December 31, 2025, on February 26, 2026.
  • The company will provide an update on recent business progress during the same February 26, 2026 event.
  • Management will host a webcast & conference call starting at 8:30 a.m. ET on February 26, 2026.
  • Conference call access details include dialing 877-407-8029 or +1 201-689-8029.
  • A replay of the webcast will be available on Aurinia's website.
  • Aurinia is a biopharmaceutical company focused on therapies for autoimmune diseases with high unmet medical needs.
  • The company introduced LUPKYNIS (voclosporin) in January 2021 as the first FDA-approved oral therapy for active lupus nephritis in adults.
  • Aurinia is developing aritinercept, a dual inhibitor of BAFF & APRIL, for the potential treatment of autoimmune diseases.